Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SUBLOCADE Clear all
Completed Phase 1Phase 2 Interventional Results available

Improving Buprenorphine Detoxification Outcomes With Isradipine

NCT01895270
View directory record Official record
Conditions
Opioid Dependence
Interventions
Isradipine, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 30, 2026, 11:36 PM EDT
Completed No phase listed Observational

Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV

NCT03976258
View directory record Official record
Conditions
HIV Infection, Opioid-use Disorder, Cardiovascular Diseases
Interventions
buprenorphine/naloxone, Methadone, Naltrexone Injection, Heroin
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 30, 2026, 11:36 PM EDT
Completed No phase listed Observational

Fetal Neurobehavioral Development in Methadone Maintained Pregnancies

NCT00067184
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Toitu 320/325
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 30, 2026, 11:36 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075

NCT03248947
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
buprenorphine/naloxone, Pharmacist-administered buprenorphine/naloxone maintenance care
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 30, 2026, 11:36 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Buprenorphine on Responses to Verbal Tasks

NCT01860287
View directory record Official record
Conditions
Basic Science
Interventions
Buprenorphine 0.2 MG Sublingual Tablet, Placebo, Buprenorphine 0.4 MG Sublingual Tablet
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 30, 2026, 11:36 PM EDT
Recruiting Phase 2 Interventional

Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use

NCT06379984
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 30, 2026, 11:36 PM EDT
Recruiting Phase 4 Interventional

Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.

NCT06323824
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Methadone, Buprenorphine (BUP)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Oakland, California • San Francisco, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 11:36 PM EDT
Completed No phase listed Observational

Evaluating the SUBLOCADE Treatment Exit Strategy

NCT05878210
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Not listed
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 30, 2026, 11:36 PM EDT
Terminated Phase 2 Interventional Results available

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

NCT04480554
View directory record Official record
Conditions
Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation, Methadone, Buprenorphine, Naltrexone, Antiretroviral Treatment
Interventions
Methadone, Buprenorphine/naloxone, XR-Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 30, 2026, 11:36 PM EDT
Completed Phase 2 Interventional

Medical Office Intervention for Adolescent Drug Use

NCT00229983
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Motivational Enhancement Therapy
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years to 21 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 30, 2026, 11:36 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical Decision Support to Increase Use of Medications for Opioid Use Disorder

NCT06526286
View directory record Official record
Conditions
Medication Abuse, Harm Reduction, Opioid Use Disorder, Supportive Care
Interventions
Medications for Opioid Use Disorder Pathway Clinical Decision Support (CDS)
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 89 Years
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 30, 2026, 11:36 PM EDT
Completed Phase 2Phase 3 Interventional

Opioid Use Disorder Treatment Linkage at Strategic Touchpoints Using Buprenorphine

NCT04991974
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Patient Navigation, Buprenorphine
Behavioral · Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 30, 2026, 11:36 PM EDT
Completed Phase 2 Interventional

HIV Risk Reduction and Drug Abuse Treatment in Malaysia

NCT00383045
View directory record Official record
Conditions
Opiate Dependence
Interventions
Buprenorphine/Subutex, Naltrexone, Drug counseling
Drug · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 30, 2026, 11:36 PM EDT
Completed Phase 3 Interventional

Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1

NCT00078130
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
14 Years to 21 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
4
States / cities
Portland, Maine • Baltimore, Maryland • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 30, 2026, 11:36 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder

NCT02672111
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
CAM2038 q1w or q4w exposure to SL BPN/NX, CAM2038 q1w or q4w new to BPN treatment
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 7 more
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 30, 2026, 11:36 PM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2

NCT00000327
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Heroin Dependence
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 62 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 30, 2026, 11:36 PM EDT
Completed Early Phase 1 Interventional

Single Injection Adductor Canal Block Versus Continuous Adductor Canal Infusion for Total Knee Arthroplasty

NCT02991404
View directory record Official record
Conditions
Total Knee Arthroplasty, Pain, Postoperative, Adductor Canal Block
Interventions
Multimodal Peripheral Nerve Block Injection, Single Shot Adductor Canal Block, Initial Bolus, Continuous infusion
Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 30, 2026, 11:36 PM EDT
Completed Phase 2 Interventional

Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence

NCT00548275
View directory record Official record
Conditions
Opiate Dependence, HIV Infections
Interventions
Enhanced Sexual Risk Management, Standard Sexual Risk Management
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 30, 2026, 11:36 PM EDT
Completed Early Phase 1 Interventional Results available

Galantamine and CBT4CBT Pilot to Prevent Relapse.

NCT03547622
View directory record Official record
Conditions
Methadone or Buprenorphine Detoxoxification
Interventions
MAT taper with galantamine, MAT taper with placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 30, 2026, 11:36 PM EDT
Active, not recruiting Not applicable Interventional

Pain Self-Management and Treatment Engagement for Patients Taking Opioids

NCT06855732
View directory record Official record
Conditions
Chronic Pain, Opioid Use Disorder, Opioid Misuse and Addiction
Interventions
Usual Care, Pain Self-Management
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
17
States / cities
Baltimore, Maryland • Allison Park, Pennsylvania • Blawnox, Pennsylvania + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 30, 2026, 11:36 PM EDT
Completed No phase listed Observational

Sustained Release d-Amphetamine & Buprenorphine on Drug Seeking Behavior in Opioid & Cocaine Dependent Individuals

NCT00429767
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Cocaine Abuse or Dependence
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 30, 2026, 11:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder

NCT06086275
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 30, 2026, 11:36 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder

NCT03745339
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 11:36 PM EDT
Terminated Phase 1 Interventional

Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

NCT06406400
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
AZD4041, Itraconazole, Buprenorphine, Buprenorphine / Naloxone, Hydromorphone, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 30, 2026, 11:36 PM EDT